Brouwer, L., Moreni, G., Wolthers, K.C. & Pajkrt, D. World-wide prevalence and genotype distribution of enteroviruses. Viruses 13, 434 (2021).
Royston, L. & Tapparel, C. Rhinoviruses and respiratory enteroviruses: not as simple as ABC. Viruses 8, 16 (2016).
Xie, Z., Khamrin, P., Maneekarn, N. & Kumthip, K. Epidemiology of enterovirus genotypes in association with human diseases. Viruses 16, 1165 (2024).
Tapparel, C., Siegrist, F., Petty, T. J. & Kaiser, L. Picornavirus and enterovirus diversity with associated human diseases. Infect. Genet. Evol. 14, 282–293 (2013).
Liu, Y. et al. A novel subgenotype C6 Enterovirus A71 originating from the recombination between subgenotypes C4 and C2 strains in mainland China. Sci. Rep. 12, 593 (2022).
Chan, Y. F., Sam, I. C. & AbuBakar, S. Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. Infect. Genet. Evol. 10, 404–412 (2010).
Aswathyraj, S., Arunkumar, G., Alidjinou, E. K. & Hober, D. Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy. Med. Microbiol. Immunol. 205, 397–407 (2016).
Huang, K. A. Structural basis for neutralization of enterovirus. Curr. Opin. Virol. 51, 199–206 (2021).
Kok, C. C., Phuektes, P., Bek, E. & McMinn, P. C. Modification of the untranslated regions of human enterovirus 71 impairs growth in a cell-specific manner. J. Virol. 86, 542–552 (2012).
Du, J. et al. Analysis of enterovirus 68 strains from the 2014 North American outbreak reveals a new clade, indicating viral evolution. PLoS ONE 10, e0144208 (2015).
Huang, K. A. et al. Structural and functional analysis of protective antibodies targeting the threefold plateau of enterovirus 71. Nat. Commun. 11, 5253 (2020).
Plevka, P., Perera, R., Cardosa, J., Kuhn, R. J. & Rossmann, M. G. Crystal structure of human enterovirus 71. Science 336, 1274 (2012).
Dang, M. et al. Molecular mechanism of SCARB2-mediated attachment and uncoating of EV71. Protein Cell 5, 692–703 (2014).
Ku, Z. et al. Single Neutralizing monoclonal antibodies targeting the VP1 GH loop of enterovirus 71 inhibit both virus attachment and internalization during viral entry. J. Virol. 89, 12084–12095 (2015).
Zhu, L. et al. Neutralization mechanisms of two highly potent antibodies against human enterovirus 71. mBio 9, e01013–18 (2018).
Lyu, K. et al. Crystal structures of enterovirus 71 (EV71) recombinant virus particles provide insights into vaccine design. J. Biol. Chem. 290, 3198–3208 (2015).
Kiener, T. K., Jia, Q., Meng, T., Chow, V. T. & Kwang, J. A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved “knob” region of VP3 protein. PLoS Negl. Trop. Dis. 8, e2895 (2014).
Baggen, J., Thibaut, H. J., Strating, J. & van Kuppeveld, F. J. M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 16, 368–381 (2018).
Yamayoshi, S., Fujii, K. & Koike, S. Receptors for enterovirus 71. Emerg. Microbes Infect. 3, e53 (2014).
Yuan, M. et al. Enhanced human enterovirus 71 infection by endocytosis inhibitors reveals multiple entry pathways by enterovirus causing hand-foot-and-mouth diseases. Virol. J. 15, 1 (2018).
Hussain, K. M., Leong, K. L., Ng, M. M. & Chu, J. J. The essential role of clathrin-mediated endocytosis in the infectious entry of human enterovirus 71. J. Biol. Chem. 286, 309–321 (2011).
Diarimalala, R. O., Hu, M., Wei, Y. & Hu, K. Recent advances of enterovirus 71 [Formula: see text] targeting Inhibitors. Virol. J. 17, 173 (2020).
Thompson, S. R. & Sarnow, P. Enterovirus 71 contains a type I IRES element that functions when eukaryotic initiation factor eIF4G is cleaved. Virology 315, 259–266 (2003).
Tan, C. W., Lai, J. K., Sam, I. C. & Chan, Y. F. Recent developments in antiviral agents against enterovirus 71 infection. J. Biomed. Sci. 21, 14 (2014).
Wei, Y. et al. Recent advances in enterovirus A71 infection and antiviral agents. Lab. Invest. 104, 100298 (2024).
Horwood, P. F. et al. Seroepidemiology of Human Enterovirus 71 Infection among Children, Cambodia. Emerg. Infect. Dis. 22, 92–95 (2016).
Yang, J. et al. Seroepidemiology of enterovirus A71 infection in prospective cohort studies of children in southern China, 2013–2018. Nat. Commun. 13, 7280 (2022).
Hagiwara, A., Tagaya, I. & Komatsu, T. Seroepidemiology of enterovirus 71 among healthy children near Tokyo. Microbiol. Immunol. 23, 121–124 (1979).
Ooi, M. H. et al. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study. Clin. Infect. Dis. 44, 646–656 (2007).
Ooi, E. E., Phoon, M. C., Ishak, B. & Chan, S. H. Seroepidemiology of human enterovirus 71, Singapore. Emerg. Infect. Dis. 8, 995–997 (2002).
Lin, T. Y., Twu, S. J., Ho, M. S., Chang, L. Y. & Lee, C. Y. Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg. Infect. Dis. 9, 291–293 (2003).
Linsuwanon, P. et al. Epidemiology and seroepidemiology of human enterovirus 71 among Thai populations. J. Biomed. Sci. 21, 16 (2014).
Tran, C. B. et al. The seroprevalence and seroincidence of enterovirus71 infection in infants and children in Ho Chi Minh City, Viet Nam. PLoS ONE 6, e21116 (2011).
Shi, Y., Chen, P., Bai, Y., Xu, X. & Liu, Y. Seroprevalence of coxsackievirus A6 and enterovirus A71 infection in humans: a systematic review and meta-analysis. Arch. Virol. 168, 37 (2023).
Lee, J. T. et al. Enterovirus 71 seroepidemiology in Taiwan in 2017 and comparison of those rates in 1997, 1999 and 2007. PLoS ONE 14, e0224110 (2019).
Chang, L. Y. et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 109, e88 (2002).
Ang, L. W. et al. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001-2007. Ann. Acad. Med. Singap. 38, 106–112 (2009).
Riller, Q., Schmutz, M., Fourgeaud, J., Fischer, A. & Neven, B. Protective role of antibodies in enteric virus infections: Lessons from primary and secondary immune deficiencies. Immunol. Rev. 328, 243–264 (2024).
Kassab, S. et al. Fatal case of enterovirus 71 infection and rituximab therapy, france, 2012. Emerg. Infect. Dis. 19, 1345–1347 (2013).
Halliday, E., Winkelstein, J. & Webster, A. D. Enteroviral infections in primary immunodeficiency (PID): a survey of morbidity and mortality. J. Infect. 46, 1–8 (2003).
Ahmed, R. et al. Enterovirus 71 meningoencephalitis complicating rituximab therapy. J. Neurol. Sci. 305, 149–151 (2011).
Weng, K. F. et al. Variant enterovirus A71 found in immune-suppressed patient binds to heparan sulfate and exhibits neurotropism in B-cell-depleted mice. Cell Rep. 42, 112389 (2023).
Puenpa, J., Wanlapakorn, N., Vongpunsawad, S. & Poovorawan, Y. The history of enterovirus A71 outbreaks and molecular epidemiology in the Asia-Pacific region. J. Biomed. Sci. 26, 75 (2019).
Xing, W. et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect. Dis. 14, 308–318 (2014).
Guo, T. et al. Seasonal Distribution and Meteorological Factors Associated with Hand, Foot, and Mouth Disease among Children in Xi’an, Northwestern China. Am. J. Trop. Med. Hyg. 102, 1253–1262 (2020).
Zeng, M. et al. Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai. J. Clin. Virol. 53, 285–289 (2012).
Ang, L. W. et al. The changing seroepidemiology of enterovirus 71 infection among children and adolescents in Singapore. BMC Infect. Dis. 11, 270 (2011).
Harvala, H. et al. Recommendations for enterovirus diagnostics and characterisation within and beyond Europe. J. Clin. Virol. 101, 11–17 (2018).
Organization, T.W.H. A Guide to Clinical Management and Public Health Response for Hand, Foot and Mouth Disease (HFMD), (World Health Organization, Manila, Philippines, 2011).
Zhou, Y. et al. Diagnostic performance of different specimens in detecting enterovirus A71 in children with hand, foot and mouth disease. Virol. Sin. 38, 268–275 (2023).
Wang, C. et al. A novel method to diagnose the infection of enterovirus A71 in children by detecting IgA from saliva. J. Med. Virol. 92, 1059–1064 (2020).
Nguyen, T. H. T. et al. Methods to discriminate primary from secondary dengue during acute symptomatic infection. BMC Infect. Dis. 18, 375 (2018).
Ooi, M. H. et al. Evaluation of different clinical sample types in diagnosis of human enterovirus 71-associated hand-foot-and-mouth disease. J. Clin. Microbiol. 45, 1858–1866 (2007).
Ooi, M. H., Wong, S. C., Lewthwaite, P., Cardosa, M. J. & Solomon, T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 9, 1097–1105 (2010).
McMinn, P. C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 26, 91–107 (2002).
Ma, E. et al. Estimation of the basic reproduction number of enterovirus 71 and coxsackievirus A16 in hand, foot, and mouth disease outbreaks. Pediatr. Infect. Dis. J. 30, 675–679 (2011).
Shen, J. et al. Relationship between serologic response and clinical symptoms in children with enterovirus 71-infected hand-foot-mouth disease. Int. J. Clin. Exp. Pathol. 8, 11608–11614 (2015).
Cheng, H. Y. et al. The correlation between the presence of viremia and clinical severity in patients with enterovirus 71 infection: a multi-center cohort study. BMC Infect. Dis. 14, 417 (2014).
Qiu, Q. et al. Kinetics of the neutralising antibody response in patients with hand, foot, and mouth disease caused by EV-A71: a longitudinal cohort study in Zhengzhou during 2017-2019. EBioMedicine 68, 103398 (2021).
Zhou, Y. et al. Comparison of neutralizing antibody response kinetics in patients with hand, foot, and mouth disease caused by coxsackievirus A16 or enterovirus A71: a longitudinal cohort study of Chinese Children, 2017–2019. J. Immunol. 209, 280–287 (2022).
Xu, F. et al. Performance of detecting IgM antibodies against enterovirus 71 for early diagnosis. PLoS ONE 5, e11388 (2010).
Chen, K., Magri, G., Grasset, E. K. & Cerutti, A. Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA. Nat. Rev. Immunol. 20, 427–441 (2020).
Zhu, F. et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N. Engl. J. Med. 370, 818–828 (2014).
Nguyen, T. T. et al. Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 399, 1708–1717 (2022).
Sun, S. et al. Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice. Hum. Vaccin Immunother. 11, 2406–2413 (2015).
Lim, P. Y. et al. Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates. Vaccine 33, 6017–6024 (2015).
Seikrit, C. & Pabst, O. The immune landscape of IgA induction in the gut. Semin. Immunopathol. 43, 627–637 (2021).
Mathias, A. & Corthesy, B. N-Glycans on secretory component: mediators of the interaction between secretory IgA and gram-positive commensals sustaining intestinal homeostasis. Gut Microbes 2, 287–293 (2011).
Mbani, C. J. et al. Enterovirus antibodies: friends and foes. Rev. Med. Virol. 34, e70004 (2024).
Ye, X. et al. Structural basis for recognition of human enterovirus 71 by a bivalent broadly neutralizing monoclonal antibody. PLoS Pathog. 12, e1005454 (2016).
Plevka, P. et al. Neutralizing antibodies can initiate genome release from human enterovirus 71. Proc. Natl. Acad. Sci. USA 111, 2134–2139 (2014).
Thomas, A. A., Vrijsen, R. & Boeye, A. Relationship between poliovirus neutralization and aggregation. J. Virol. 59, 479–485 (1986).
Watkinson, R. E., McEwan, W. A., Tam, J. C., Vaysburd, M. & James, L. C. TRIM21 promotes cGAS and RIG-I sensing of viral genomes during infection by antibody-opsonized virus. PLoS Pathog. 11, e1005253 (2015).
Du, R. et al. Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism. Emerg. Microbes Infect. 12, 2149352 (2023).
Behzadi, M. A. et al. A cross-reactive mouse monoclonal antibody against rhinovirus mediates phagocytosis in vitro. Sci. Rep. 10, 9750 (2020).
Gao, F. et al. Enterovirus 71 viral capsid protein linear epitopes: identification and characterization. Virol. J. 9, 26 (2012).
Aw-Yong, K. L., Sam, I. C., Koh, M. T. & Chan, Y. F. Immunodominant IgM and IgG epitopes recognized by antibodies induced in enterovirus A71-associated hand, foot and mouth disease patients. PLoS ONE 11, e0165659 (2016).
Zhang, H. et al. Genome-wide linear B-cell epitopes of enterovirus 71 in a hand, foot and mouth disease (HFMD) population. J. Clin. Virol. 105, 41–48 (2018).
Xu, L. et al. Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop. Theranostics 4, 498–513 (2014).
Aw-Yong, K. L., NikNadia, N. M. N., Tan, C. W., Sam, I. C. & Chan, Y. F. Immune responses against enterovirus A71 infection: implications for vaccine success. Rev. Med. Virol. 29, e2073 (2019).
You, L. et al. Antibody signatures in hospitalized hand, foot and mouth disease patients with acute enterovirus A71 infection. PLoS Pathog. 19, e1011420 (2023).
Wang, L. et al. Bioinformatics-based prediction of conformational epitopes for Enterovirus A71 and Coxsackievirus A16. Sci. Rep. 11, 5701 (2021).
Saarinen, N.V.V. et al. Multiplexed high-throughput serological assay for human enteroviruses. Microorganisms 8, 1426 (2020).
Vatti, A. et al. Original antigenic sin: a comprehensive review. J. Autoimmun. 83, 12–21 (2017).
Tsuchiya, H., Furukawa, M., Matsui, M., Katsuki, K. & Inouye, S. Original antigenic sin’ phenomenon in neutralizing antibody responses in children with enterovirus meningitis. J. Clin. Virol. 19, 205–207 (2000).
Han, J. F. et al. Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virol. J. 8, 106 (2011).
Hawkes, R. A. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust. J. Exp. Biol. Med. Sci. 42, 465–482 (1964).
Halstead, S. B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60, 421–467 (2003).
Takada, A. & Kawaoka, Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev. Med. Virol. 13, 387–398 (2003).
Shukla, R., Ramasamy, V., Shanmugam, R. K., Ahuja, R. & Khanna, N. Antibody-dependent enhancement: a challenge for developing a safe dengue vaccine. Front. Cell Infect. Microbiol. 10, 572681 (2020).
Narayan, R. & Tripathi, S. Intrinsic ADE: the dark side of antibody dependent enhancement during dengue infection. Front. Cell Infect. Microbiol. 10, 580096 (2020).
Thomas, S. et al. Antibody-dependent enhancement (ADE) and the role of complement system in disease pathogenesis. Mol. Immunol. 152, 172–182 (2022).
Nicholson-Weller, A. & Klickstein, L. B. C1q-binding proteins and C1q receptors. Curr. Opin. Immunol. 11, 42–46 (1999).
Guillon, C., Schutten, M., Boers, P. H., Gruters, R. A. & Osterhaus, A. D. Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction. J. Virol. 76, 2827–2834 (2002).
Hu, K., Onintsoa Diarimalala, R., Yao, C., Li, H. & Wei, Y. EV-A71 mechanism of entry: receptors/co-receptors, related pathways and inhibitors. Viruses 15, 785 (2023).
He, Y. et al. Structures of foot-and-mouth disease virus with neutralizing antibodies derived from recovered natural host reveal a mechanism for cross-serotype neutralization. PLoS Pathog. 17, e1009507 (2021).
Wang, S. M. et al. Enterovirus 71 infection of monocytes with antibody-dependent enhancement. Clin. Vaccin. Immunol. 17, 1517–1523 (2010).
Coudere, K. et al. Neutralising antibodies against enterovirus and parechovirus in IVIG reflect general circulation: a tool for sero-surveillance. Viruses 13, 1028 (2021).
Cao, R. et al. Presence of high-titer neutralizing antibodies against enterovirus 71 in intravenous immunoglobulin manufactured from Chinese donors. Clin. Infect. Dis. 50, 125–126 (2010).
Chen, I. C., Wang, S. M., Yu, C. K. & Liu, C. C. Subneutralizing antibodies to enterovirus 71 induce antibody-dependent enhancement of infection in newborn mice. Med. Microbiol. Immunol. 202, 259–265 (2013).
Cao, R. Y. et al. Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection. PLoS ONE 8, e64024 (2013).
Sauter, P. & Hober, D. Mechanisms and results of the antibody-dependent enhancement of viral infections and role in the pathogenesis of coxsackievirus B-induced diseases. Microbes Infect. 11, 443–451 (2009).
Elmastour, F. et al. Immunoglobulin G-dependent enhancement of the infection with Coxsackievirus B4 in a murine system. Virulence 7, 527–535 (2016).
Kishimoto, C., Kurokawa, M. & Ochiai, H. Antibody-mediated immune enhancement in coxsackievirus B3 myocarditis. J. Mol. Cell Cardiol. 34, 1227–1238 (2002).
Yu, J. Z. et al. Secondary heterotypic versus homotypic infection by Coxsackie B group viruses: impact on early and late histopathological lesions and virus genome prominence. Cardiovasc. Pathol. 8, 93–102 (1999).
Aswathyraj, S. et al. Serum-derived IgG from coxsackievirus A6-infected patients can enhance the infection of peripheral blood mononuclear cells with coxsackievirus A6. Microb. Pathog. 125, 7–11 (2018).
Chehadeh, W., Bouzidi, A., Alm, G., Wattre, P. & Hober, D. Human antibodies isolated from plasma by affinity chromatography increase the coxsackievirus B4-induced synthesis of interferon-alpha by human peripheral blood mononuclear cells in vitro. J. Gen. Virol. 82, 1899–1907 (2001).
Alidjinou, E. K., Sane, F., Engelmann, I. & Hober, D. Serum-dependent enhancement of coxsackievirus B4-induced production of IFNalpha, IL-6 and TNFalpha by peripheral blood mononuclear cells. J. Mol. Biol. 425, 5020–5031 (2013).
Morvan, C., Nekoua, M. P., Debuysschere, C., Alidjinou, E. K. & Hober, D. Antibody-dependent enhancement and neutralization against CVB4 investigated in vitro and in silico through an agent-based model. J. Med. Virol. 96, e29399 (2024).
Che, Z. et al. Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes. J. Virol. 72, 4610–4622 (1998).
Jiao, W. et al. The effectiveness of different doses of intravenous immunoglobulin on severe hand, foot and mouth disease: a meta-analysis. Med. Princ. Pract. 28, 256–263 (2019).
Li, R. et al. An inactivated enterovirus 71 vaccine in healthy children. N. Engl. J. Med. 370, 829–837 (2014).
Liu, L. et al. Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations. BMC Med. 13, 226 (2015).
Hu, Y. et al. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: a further observation. Hum. Vaccin. Immunother. 14, 1517–1523 (2018).
Zhu, F. C. et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381, 2024–2032 (2013).
Yang, T. et al. Safety and immunogenicity of an experimental live combination vaccine against enterovirus 71 and coxsackievirus A16 in rhesus monkeys. Hum. Vaccin. Immunother. 16, 1586–1594 (2020).
Kim, H. J. et al. Efficient expression of enterovirus 71 based on virus-like particles vaccine. PLoS ONE 14, e0210477 (2019).
Maje Bello, A., Chaimongkolnukul, K., Poomputsa, K., Mekvichitsaeng, P. & Maprang Roshorm, Y. Immunogenicity and immunodominant linear B-cell epitopes of a new DNA-based tetravalent vaccine against four major enteroviruses causing hand, foot, and mouth disease. Vaccine 42, 3733–3743 (2024).
Yee, P. T. & Poh, C. L. Development of novel miRNA-based vaccines and antivirals against enterovirus 71. Curr. Pharm. Des. 22, 6694–6700 (2016).
Liu, Z. et al. A novel polypeptide vaccine and adjuvant formulation of EV71. Pathog. Dis. 79, ftab057 (2022).
Chen, H. F., Chang, M. H., Chiang, B. L. & Jeng, S. T. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 24, 2944–2951 (2006).
Hu, Q. et al. Effectiveness of EV-A71 vaccine and its impact on the incidence of hand, foot and mouth disease: a systematic review. Vaccines 12, 1028 (2024).
Wei, M. et al. 2-Year efficacy, immunogenicity, and safety of vigoo enterovirus 71 vaccine in healthy chinese children: a randomized open-label study. J. Infect. Dis. 215, 56–63 (2017).
Ye, L. et al. Vaccination coverage estimates and utilization patterns of inactivated enterovirus 71 vaccine post vaccine introduction in Ningbo, China. BMC Public Health 21, 1118 (2021).
Zheng, D. et al. Effect of EV71 vaccination on transmission dynamics of hand, foot, and mouth disease and its epidemic prevention threshold. Vaccines 12, 1166 (2024).
Liu, Y. et al. Effectiveness of the enterovirus A71 vaccine on hand, foot and mouth disease: a real-world study in China. Clin. Microbiol. Infect. 31, 258–265 (2024).
Jiang, H. et al. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China. Emerg. Microbes Infect. 10, 619–628 (2021).
Wang, M. et al. The spatial-temporal distribution and etiological characteristics of hand-foot-and-mouth disease before and after EV‑A71 vaccination in Kunming, China, 2017-2020. Sci. Rep. 12, 17028 (2022).
Duan, X. et al. Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease profile of post-vaccination infection. Vaccine 42, 2317–2325 (2024).
Lizasoain, A., Mir, D., Martinez, N. & Colina, R. Coxsackievirus A10 causing hand-foot-and-mouth disease in Uruguay. Int. J. Infect. Dis. 94, 1–3 (2020).
Mao, Q. et al. The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children. PLoS ONE 8, e79599 (2013).
Li, J. X. et al. Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert Rev. Vaccines 15, 129–137 (2016).
Zeng, H. et al. Emergence of a non vaccine-cognate enterovirus A71 genotype C1 in mainland China. J. Infect. 82, 407–413 (2021).
Xiao, J. et al. The impact of enterovirus A71 vaccination program on hand, foot, and mouth disease in Guangdong, China: a longitudinal surveillance study. J. Infect. 85, 428–435 (2022).
Liu, H. B. et al. A 5-year molecular epidemiology survey of human enterovirus 71 before vaccine application in Yunnan Province, China. J. Med. Virol. 92, 1085–1092 (2020).
Chou, A. H. et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS ONE 8, e79783 (2013).
Huang, L. M. et al. Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan. Vaccine 37, 1827–1835 (2019).
Cheng, A. et al. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 31, 2471–2476 (2013).
Yi, E. J. et al. A bivalent inactivated vaccine prevents enterovirus 71 and coxsackievirus A16 infections in the Mongolian Gerbil. Biomol. Ther.31, 350–358 (2023).
Lin, C. W. et al. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems. Biomed. Res. Int. 2014, 670506 (2014).
Caine, E. A., Fuchs, J., Das, S. C., Partidos, C. D. & Osorio, J. E. Efficacy of a trivalent hand, foot, and mouth disease vaccine against enterovirus 71 and coxsackieviruses A16 and A6 in mice. Viruses 7, 5919–5932 (2015).
Barcena, J., Zamora-Ceballos, M. & Blanco, E. Design of novel vaccines based on virus-like particles. Subcell. Biochem. 105, 785–821 (2024).
Li, H. Y., Han, J. F., Qin, C. F. & Chen, R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 31, 3281–3287 (2013).
Zhao, H. et al. Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice. Sci. Rep. 5, 7878 (2015).
Issaro, N. et al. Induction of immune responses by a novel recombinant fusion protein of enterovirus A71 in BALB/c mice. Mol. Immunol. 105, 1–8 (2019).
Meng, T., Kolpe, A. B., Kiener, T. K., Chow, V. T. & Kwang, J. Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice. PLoS ONE 6, e21757 (2011).
Kolpe, A. B., Kiener, T. K., Grotenbreg, G. M. & Kwang, J. Display of enterovirus 71 VP1 on baculovirus as a type II transmembrane protein elicits protective B and T cell responses in immunized mice. Virus Res. 168, 64–72 (2012).
Lin, X. et al. A novel peptide from VP1 of EV-D68 exhibits broad-spectrum antiviral activity against human enteroviruses. Biomolecules 14, 1331 (2024).
Zhao, M. et al. Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses. BMC Microbiol. 13, 287 (2013).
Xu, L. et al. A broadly cross-protective vaccine presenting the neighboring epitopes within the VP1 GH loop and VP2 EF loop of enterovirus 71. Sci. Rep. 5, 12973 (2015).
Lin, T. Y. et al. The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. Clin. Infect. Dis. 34, S52–57 (2002).
Liu, C. C. et al. Identification and characterization of a cross-neutralization epitope of enterovirus 71. Vaccine 29, 4362–4372 (2011).
Yee, P. T. I. et al. Development of live attenuated Enterovirus 71 vaccine strains that confer protection against lethal challenge in mice. Sci. Rep. 9, 4805 (2019).
Chen, N. & Zhang, B. The strategies used by animal viruses to antagonize host antiviral innate immunity: new clues for developing live attenuated vaccines (LAVs). Vaccines (Basel) 13, 46 (2025).
Sadeghipour, S., Bek, E. J. & McMinn, P. C. Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture. J. Virol. 87, 1759–1769 (2013).
Vignuzzi, M., Wendt, E. & Andino, R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat. Med. 14, 154–161 (2008).
Vignuzzi, M., Stone, J. K., Arnold, J. J., Cameron, C. E. & Andino, R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439, 344–348 (2006).
Barnes, D., Kunitomi, M., Vignuzzi, M., Saksela, K. & Andino, R. Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe 4, 239–248 (2008).
Mendoza, E. J., Racine, T. & Kobinger, G. P. The ongoing evolution of antibody-based treatments for Ebola virus infection. Immunotherapy 9, 435–450 (2017).
Zhu, R. et al. Broadly therapeutic antibody provides cross-serotype protection against enteroviruses via Fc effector functions and by mimicking SCARB2. Nat. Microbiol. 9, 2939–2953 (2024).
Li, Y., Yu, J., Qi, X. & Yan, H. Monoclonal antibody against EV71 3D(pol) inhibits the polymerase activity of RdRp and virus replication. BMC Immunol. 20, 6 (2019).
Li, Z. et al. In vivo time-related evaluation of a therapeutic neutralization monoclonal antibody against lethal enterovirus 71 infection in a mouse model. PLoS ONE 9, e109391 (2014).
Zhou, B. et al. A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential. Antivir. Res. 161, 28–35 (2019).
Xu, L. et al. Monoclonal antibodies for diagnosis of enterovirus 71. Monoclon. Antib. Immunodiagn. Immunother. 32, 386–394 (2013).
Zhang, X. et al. The binding of a monoclonal antibody to the apical region of SCARB2 blocks EV71 infection. Protein Cell 8, 590–600 (2017).
Lum, L. C. et al. Fatal enterovirus 71 encephalomyelitis. J. Pediatr. 133, 795–798 (1998).
Lim, X. F. et al. Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS ONE 7, e29751 (2012).
Zhu, W. et al. Dual blockages of a broad and potent neutralizing IgM antibody targeting GH loop of EV-As. Immunology 169, 292–308 (2023).
Zhu, W. et al. A broad and potent IgM antibody against tetra-EV-As induced by EVA71 and CVA16 co-immunization. Vaccine 39, 6510–6519 (2021).
Ledford, H. Antibody therapies could be a bridge to a coronavirus vaccine — but will the world benefit? (Nature, 2020).
O’Hagan, S., Galway, N., Shields, M. D., Mallett, P. & Groves, H. E. Review of the safety, efficacy and tolerability of palivizumab in the prevention of severe respiratory syncytial virus (RSV) disease. Drug Health Patient Saf. 15, 103–112 (2023).
Rayaprolu, V. et al. Structure of the Inmazeb cocktail and resistance to Ebola virus escape. Cell Host Microbe 31, 260–272.e267 (2023).
Muslin, C., Mac Kain, A., Bessaud, M., Blondel, B. & Delpeyroux, F. Recombination in enteroviruses, a multi-step modular evolutionary process. Viruses 11, 859 (2019).
Rosenfeld, A. B. et al. Cross-Reactive Antibody Responses against Nonpoliovirus Enteroviruses. mBio 13, e0366021 (2022).
Wegman, A. D. et al. DENV-specific IgA contributes protective and non-pathologic function during antibody-dependent enhancement of DENV infection. PLoS Pathog. 19, e1011616 (2023).
Nekoua, M. P., Alidjinou, E. K. & Hober, D. Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus. Nat. Rev. Endocrinol. 18, 503–516 (2022).
Op de Beeck, A. & Eizirik, D. L. Viral infections in type 1 diabetes mellitus-why the beta cells?. Nat. Rev. Endocrinol. 12, 263–273 (2016).
Harkonen, T. et al. Enterovirus infection may induce humoral immune response reacting with islet cell autoantigens in humans. J. Med. Virol. 69, 426–440 (2003).
Bubba, L. et al. Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a retrospective surveillance study. Lancet Infect. Dis. 20, 350–361 (2020).
Liu, J. N. et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 28, 7444–7451 (2010).
Martinez-Gualda, B. et al. Scaffold simplification strategy leads to a novel generation of dual human immunodeficiency virus and enterovirus-A71 entry inhibitors. J. Med. Chem. 63, 349–368 (2020).
Foo, D. G. et al. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 125, 61–68 (2007).
Lidbury, B. A. & Mahalingam, S. Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection. J. Virol. 74, 8376–8381 (2000).
Mahalingam, S. & Lidbury, B. A. Suppression of lipopolysaccharide-induced antiviral transcription factor (STAT-1 and NF-kappa B) complexes by antibody-dependent enhancement of macrophage infection by Ross River virus. Proc. Natl. Acad. Sci. USA 99, 13819–13824 (2002).
